A7986
阿托伐醌
≥98% (HPLC), powder, anti-protozoal agent
别名:
Mepron, 反式-2-[4-（4-氯苯基）环己基]-3-羟基-1,4-萘二酮
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H19ClO3
化学文摘社编号:
分子量:
366.84
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
产品名称
阿托伐醌, ≥98% (HPLC)
SMILES string
OC1=C([C@H]2CC[C@@H](CC2)c3ccc(Cl)cc3)C(=O)c4ccccc4C1=O
InChI
1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-
InChI key
KUCQYCKVKVOKAY-CTYIDZIISA-N
assay
≥98% (HPLC)
form
powder
color
yellow
solubility
DMSO: >10 mg/mL
originator
GlaxoSmithKline
storage temp.
−20°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
抗原生动物线粒体电子传递抑制剂中的阿托伐醌。 它还具有抗疟药和抗肺囊虫药的作用。
阿托伐醌是一种抗原生动物线粒体电子传递抑制剂；抗疟药；抗肺囊虫药，也已用于治疗弓形虫病。它是原生动物线粒体蛋白泛醌的类似物，并通过与泛醇氧化口袋中的Rieske铁硫蛋白和细胞色素b相互作用抑制细胞色素bc（1）复合物起作用。
Application
Atovaquone inhibits the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket. In addition to its use as a treatment for toxoplasmosis, atovaquone has antimalarial properties and prevents pneumocystis pneumonia post-renal transplant.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Kai J Rogers et al.
Cell reports, 30(12), 4041-4051 (2020-03-27)
During the 2013-2016 Ebola virus (EBOV) epidemic, a significant number of patients admitted to Ebola treatment units were co-infected with Plasmodium falciparum, a predominant agent of malaria. However, there is no consensus on how malaria impacts EBOV infection. The effect
Steven Gabardi et al.
Clinical transplantation, 26(3), E184-E190 (2012-04-11)
Pneumocystis pneumonia (PCP) is associated with significant morbidity and mortality in renal transplant recipients (RTR). Trimethoprim-sulfamethoxazole (TMP-SMZ) is considered the prophylactic agent-of-choice. Some patients require an alternative owing to TMP-SMZ intolerance. This is the first evaluation of full-dose atovaquone vs.
Zehua Song et al.
Antimicrobial agents and chemotherapy, 59(7), 4053-4058 (2015-04-29)
The bc1 complex is central to mitochondrial bioenergetics and the target of the antimalarial drug atovaquone that binds in the quinol oxidation (Qo) site of the complex. Structural analysis has shown that the Qo site residue Y279 (Y268 in Plasmodium
Mikio Kimura et al.
Parasitology international, 61(3), 466-469 (2012-04-10)
Malaria remains an important health risk among travelers to tropical/subtropical regions. However, in Japan, only 2 antimalarials are licensed for clinical use - oral quinine and mefloquine. The Research Group on Chemotherapy of Tropical Diseases introduced atovaquone-proguanil in 1999, and
M Cella et al.
Clinical pharmacology and therapeutics, 91(4), 726-733 (2012-03-09)
Concurrent prescription of different drugs is common and is often necessary in many pediatric indications. A randomized concentration-controlled trial (RCCT) is proposed for pediatric studies in which drug combinations are used. The aim of our investigation was to show the
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持